FDA & Government News

Exercise in a Pill Is Now in Human Trials

Atrogi's ATR-258 just dosed its first subjects — and the muscle data it's hunting could reframe how we treat weight loss.

Share

  • 1

    ATR-258 is a β2-agonist that aims for fat loss while preserving muscle.

  • 2

    Safety was confirmed in a 69-subject Phase 1 trial.

  • 3

    The new study focuses on overweight male volunteers.

  • 4

    Key metrics include muscle physiology data and functional measures.

  • 5

    The trial duration is 8 weeks, with results expected later this year.

Original Source(s)

Exercise in a Pill Is Now in Human Trials

  • by Kerri Miller

  • March 18, 2026

Related Content

AI Is Already Screening Residency Applicants — Before the Legal Rules Are Clear

Programs are rapidly adopting AI-based review tools for residency applications, even as questions remain about accuracy, discrimination risk, and who is accountable when the systems get it wrong.

Inter Miami CF Renews Longstanding Multilayered Partnership with Baptist Health 

Baptist Health Continues Partnership as Inter Miami CF’s Official Medical Team and becomes a Founding Partner of Miami Freedom Park

  • by

  • March 18, 2026

  • 4 min
ADA voices support for reintroduction of Promoting Dental Health Act

The ADA supports legislation reintroduced in the U.S. Senate that would extend federal support for oral health initiatives nationwide.